Jefferies Maintains Buy on CytomX Therapeutics, Inc. (CTMX) $16 PT Mar 2026

CTMX analyst rating: Jefferies on March 18, 2026 maintained its Buy on CytomX Therapeutics, Inc. (CTMX) and raised the price target to $16. The firm called CTMX a “buying opportunity here.” The move keeps Jefferies’ positive stance while upping expected value per share. This article explains the action, the $16 price target, market reaction, and what the maintained Buy means for investors.

CTMX analyst rating: Jefferies action and details

Jefferies maintained a Buy on CytomX Therapeutics, Inc. (CTMX) on March 18, 2026 and lifted its price target to $16. The StreetInsider report quotes Jefferies calling CTMX a buying opportunity and notes the new target. The firm’s note appeared at 10:16 AM ET and shows analyst conviction without changing the Buy stance. source

Price target change and market reaction

Jefferies’ new price target is $16, an upward revision that signals expected upside versus prior assumptions. The published note lists a -12.08% ($-0.58) price change since the note’s reference point. Market quotes and chart context are available on MarketWatch for intraday and recent trading checks. source

What a maintained Buy means for investors

A maintained Buy with a higher price target shows the analyst sees more value today than before. Investors should view this as continued confidence in CytomX Therapeutics, Inc. (CTMX) fundamentals or catalysts. The call is not a guarantee; it is an analyst view based on drug development milestones and commercial potential.

Historical analyst coverage and context for CTMX

Recent coverage on CTMX has been concentrated and visible through selective firms like Jefferies. That concentration means single-firm notes can move sentiment more than broad consensus. Investors should weigh Jefferies’ view against any prior or concurrent notes and company news before changing positions.

Valuation, market cap and key metrics

CytomX Therapeutics, Inc. shows a market cap of $718,189,140, a metric Jefferies likely considered when setting the $16 target. Price targets compare expected share value to current trading levels and market capitalization. Investors should check recent financials and upcoming catalysts to align valuation with risk.

Meyka AI perspective and short-term outlook

Meyka AI rates CTMX with a grade of B+. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Our AI-powered market analysis flags Jefferies’ maintained Buy and higher PT as a positive catalyst, but notes concentrated coverage and clinical risk as balancing factors.

Final Thoughts

Jefferies’ March 18, 2026 note kept a Buy on CytomX Therapeutics, Inc. (CTMX) while raising the price target to $16, which signals continued analyst confidence. The maintained Buy is a positive endorsement, but it depends on upcoming clinical and commercial milestones.

Investors should treat the CTMX analyst rating as one input. Meyka AI rates CTMX with a grade of B+, reflecting relative strength versus benchmarks and analyst views. Use this rating with portfolio goals, risk tolerance, and company news before making decisions. Ratings and targets can change, and this is not financial advice.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Analyst ratings are opinions and not guarantees of future performance. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.